[HTML][HTML] Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
Journal of clinical oncology, 2009•ncbi.nlm.nih.gov
Purpose A randomized, phase III trial demonstrated superiority of sunitinib over interferon
alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for
metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are
reported.
alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for
metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are
reported.
Abstract
Purpose
A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported.
ncbi.nlm.nih.gov